Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02742727 2016-12-06

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Phase 1/2 Unknown

10 enrolled

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02944162 2016-12-06

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Phase 1/2 Unknown

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01146262 2016-07-26

CD lam

Phase 1/2 Unknown

5 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01369368 2015-06-24

Treatment of Acute Leukemia Relapse After Allotransplantation

Phase 1/2 Unknown

20 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02007811 2014-03-26

B-cell therapy

Phase 1/2 Unknown

15 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00242515 2014-01-08

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Phase 1/2 Unknown

16 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01037556 2012-08-31

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Phase 1/2 Unknown

50 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00838240 2012-07-20

AML-14A

Phase 1/2 Unknown

114 enrolled

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00887042 2012-03-26

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Phase 1/2 Unknown

35 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01534702 2012-02-20

CIARA

Phase 1/2 Unknown

60 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01513109 2012-01-20

ASCI

Phase 1/2 Unknown

20 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

RELAX

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Venetoclax and Lintuzumab-Ac225 in AML Patients

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

PA001

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)

Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia

Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

Multiple CAR-T Cell Therapy Targeting AML

Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

TRANSATRA

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

AML

PANOBEST

GLIDE

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

CD lam

Treatment of Acute Leukemia Relapse After Allotransplantation

B-cell therapy

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

AML-14A

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

CIARA

ASCI